Medi RSO 1:40 Feminised Seeds

$12.34$44.81

Please select pack size below

We send seeds in discreet stealth packaging worldwide.

We're Social - Spread the Love

Medi RSO 1:40 Feminised Cannabis Seeds by Medical Marijuana Genetics

A 60% indica hybrid, Medi RSO 1:40 Feminised is a high THC strain specially designed for the purpose of making ‘Rick Simpson oil’. Therefore, ideal to treat patients who suffer with chronic pain. Rick Simpson’s seminal film ‘Run from the Cure’, where he documented his successful treatment of his own skin cancer. Using topically applied cannabis oil he heralded a global movement of cannabis oil as a viable treatment for cancer.

Although we would never make the claim that cannabis is a cure for cancer. There is nevertheless pre-clinical evidence from The Complutense University of Madrid, a public research university, and St.George’s university. These results show THC to actively target and kill cancer cells (apotheosis).

Medi RSO 1:40 Feminised has been created by Medical Marijuana Genetics from the original Northern Lights strain. As a result, she produces dense buds with peppery and lemon flavours thanks to her good levels of the terpene limonene. Indoors plants take 9 weeks to complete the flowering phase yielding about 500 gr/m2. Outdoors each plant can produce up to 700 gr. While THC production is high at 23%, the level of CBD is around 0.5%. Her effect is powerful yet soothing and relaxing.

Rick Simpson Oil is recommended for use by those suffering from pain due to cancer and other chronic pain conditions such as sciatica, nerve damage, cluster headaches and multiple sclerosis.

Buy Medical marijuana genetics’ Medi RSO 1 :40 Feminised medicinal cannabis seeds form the internets best value seed shop – Coffee shop seeds

Characteristics

Additional information

Breeder: No selection

Genetics: No selection

Northern Lights selection

Variety: No selection

Mostly Indica

Flowering Time: No selection

63 days

Flowering Type: No selection

Photoperiod

Sex: No selection

Feminised

CBD Content: No selection

0.50%

THC Content: No selection

23%

Yield: No selection

High

Grows: No selection

Grows Indoors, Grows outdoors

Medical Conditions: No selection

, , , , , ,

Medical Properties: No selection

Yes

Effect: No selection

, ,

Flavour: No selection

,

Brand

Medical Marijuana Genetics

Medical Marijuana Genetics first learnt of the therapeutic properties of the cannabis plant in 2014. Whilst desperately treating the symptoms of one of the founders mother’s late stage pancreatic cancer. Not long after her first dose of cannabis oil, she was able to move around relatively pain free. This enabled her to tend to her beloved garden, in the weeks leading up to her death. Medical Marijuana Genetics teamed with award winning breeders from Spain, with the initial aim of creating a line of CBD dominant cannabis strains. Using genetics from a number of well established strains, Medical Marijuana Genetics successfully created Candida (CD-1). Aptly named after the founder’s mother and meaning ‘bright light’ in Latin. Medical Marijuana Genetics have had results ranging from 20.65% CBD with 0.7% THC to 10.65% CBD to 0.39% THC. These percentages represent the highest known consistent ratios in a CBD-rich seed strain ever created in Europe. Medical Marijuana Genetics created a further 12 elite strains using Candida as a parent. They have selected their favourite's of these to release alongside their flagship Candida strain. These have been selected to provide access (within lawful jurisdiction) to the widest range of therapeutics that the cannabis plant, and CBD in particular, has to offer. This includes treatments for symptoms such chronic pain, inflammation, seizures, convulsions, gastro-intestinal disorders, nausea, vomiting, skin conditions, bacterial infections, anxiety, depression, cancer cell growth and much more. All of the strains that are being launched are CBD dominant and have a CBD content of over 8%, but some strains veer towards a 1:1 ratio. In 2017 MMG strains won 5 Spannabis Champions Cups in Barcelona and Madrid. The awards include a 1st (BCN), 2nd and 3rd place (MAD)  in CBD categories for Orinoco OR1, Candida CD1 and Nightingale NN1 and a 2nd and 3rd in the Indica category for as yet unreleased genetics.
Medical marijuana Genetics Cannabis Seed breeders

Customer reviews

Reviews

There are no reviews yet.

Be the first to review “Medi RSO 1:40 Feminised Seeds”

Use one of the allowed file type: jpg,png.